AlloCure raises $25mn to take lead stem cell therapy into Phase II
This article was originally published in Scrip
Executive Summary
AlloCure has raised $25 million in a Series B financing round involving one new investor, Lundbeckfond Ventures, which becomes the second Danish corporate venture fund to invest in the Burlington, Massachusetts-based biotech company.